Author: S. C. Springmeyer1, J. R. Jett2; Medical, Biodesix, Boulder, CO, United States, National Jewish Health, Denver, CO, United States
We are pleased to share details on the presentations and new data that will be presented at ATS 2021.
Registered attendees, please visit our booth in the virtual exhibit hall to learn more.
Author: S. C. Springmeyer1, J. R. Jett2; Medical, Biodesix, Boulder, CO, United States, National Jewish Health, Denver, CO, United States
Nodify Lung™ testing consists of two blood-based proteomic tests (the Nodify CDT™ & Nodify XL2® tests) to help physicians reclassify risk of cancer and aid in stratifying patients into distinct nodule management pathways: intervention or surveillance.
Biodesix Lung Reflex® testing consists of the GeneStrat® tumor profiling test and the VeriStrat® immune profiling test to provide physicians with timely molecular results to facilitate treatment decisions for patients with non-small cell lung cancer.
We provide biopharmaceutical companies with end-to-end diagnostic services inclusive of diagnostic research and feasibility, assay development, clinical trial testing, and commercialization of companion diagnostics.
Fill out the form below to be notified when the poster is available.
A leading data-driven diagnostic solutions company helping answer critical clinical questions faced by physicians, researchers, and biopharmaceutical companies, with a primary focus in lung disease.
CORPORATE HEADQUARTERS
2970 Wilderness Place, Suite 100
Boulder, CO 80301
Phone (303) 417-0500
Fax (866) 432-3338
© Copyright 2021 Biodesix.
All Rights Reserved.